Abstract: Mizolastine is a selective histamine H1 receptor antagonist for chronic urticaria or allergic rhinitis. We investigated whether the variant genotypes of metabolic enzymes UGT1A1, CYP3A5 and transporter ABCB1 influence pharmacokinetic phenotype of substrate mizolastine in Chinese volunteers. Genotyping of single nucleotide polymorphisms in UGT1A1*6 (G211A), CYP3A5*3 (A6986G) and ABCB1 (C3435T) was determined by the pyrosequencing method. After a single oral dose of 10 mg mizolastine, the plasma concentrations were measured using validated high-performance liquid chromatography in 24 Chinese healthy volunteers. The results showed that the distributions of wild-type homozygotes and variant allele carriers (the sum of variant heterozygotes and variant homozygotes) were as follows: 17 cases (70.8%) versus seven cases (29.2%) in UGT1A1*6 genotypes, five cases (20.8%) versus 19 cases (79.2%) in CYP3A5*3 genotypes and seven cases (29.2%) versus 17 cases (70.8%) in ABCB1 3435T genotypes, respectively. There were no significant differences in pharmacokinetic parameters of mizolastine between the variant allele UGT1A1*6, CYP3A5*3 and ABCB1 3435T carriers and the wild-type homozygotes, and the ratios were as follows: C max was 101.03%, 86.02% and 105.78%; T max was 162.35%, 98.98% and 144.90%; AUC 0-28 was 113.04%, 77.35% and 112.71%; and t 1/2 was 95.77%, 72.40% and 100.97%, respectively. In conclusion, these results suggested that the UGT1A1, CYP3A5 and ABCB1 genetic polymorphisms might be not contributed to the interindividual variation of mizolastine pharmacokinetic phenotype in the Chinese population.
Mizolastine is a second-generation selective histamine H1 receptor antagonist which has both anti-allergic and antiinflammatory actions through suppression of the histamine release from mast cells [1, 2] . Mizolastine effectively inhibits anaphylactic cutaneous reaction including weal and flare, thus it is the first-line drug used for treatment of chronic idiopathic urticaria and allergic rhinitis in the clinic [3] . It has been confirmed that oral administration of mizolastine is well absorbed and metabolized extensively in vivo [4] . The main metabolic pathway of mizolastine is hepatic glucuronidation by II phase enzyme glucuronosyltransferases (UGTs), while minor metabolic pathways including oxidation, hydroxylation and dealkylation by hepatic I phase enzymes cytochrome P450 3A (CYP 3A4/5), despite more rare metabolism such as sulfotransferases, CYP2A6 and CYP2D6 isoenzymes, have also been reported [5] [6] [7] [8] . Moreover, recently, it has been reported that the transporter ABCB1 (ATP-binding cassette subfamily B member 1) is also involved in the disposition of mizolastine especially in central distribution due to its one of the substrate drugs via transporter ABCB1 [9] [10] [11] [12] . It has been reported that mizolastine has diverse response in patients and even no benefit. However, little is known about the exact mechanism of the interindividual variations in mizolastine.
Uridine diphosphate (UDP)-glucuronosyltransferases (UGTs) are a group of phase II enzymes that mediate more than one-third of phase II drug metabolism and influence the plasma levels and the clearance of a given compound [13] . Among more than nine important UGTs enzymes, UGT1A1 isoform mainly distributes in liver and is one of the most studied UGT1A enzymes [14] . The UGT1A1*6 (211G>A, G71R) polymorphism on exon 1 of the UGT1A1 gene has less activity than wild-type UGT1A1*1 [15] . It is reported that UGT1A1*6 is most frequent in a total of five polymorphisms of UGT1A1 in Chinese population, while it is missing or there are only very few in Caucasians or African-Americans [16] [17] [18] . The mutation of UGT1A1*6 gene is more common in Chinese populations than in Caucasian populations [19, 20] . The most frequent and common single nucleotide polymorphism (SNPs) of CYP3A gene family is CYP3A5*3 (6986A>G) transition within intron 3, and this transition creates an alternative splice site in the pre-mRNA, leading to the production of aberrant mRNA with a premature stop codon [21] . CYP3A5*3 homozygotes lack CYP3A5 expression, while individuals with at least one CYP3A5*1 wild-type allele express CYP3A5 [22] . Polymorphic expression of CYP3A5 may account for some of the interindividual and interethnic variation in clearance of CYP3A substrates [23, 24] . ABCB1 gene encodes P-glycoprotein (P-gp, or multidrug-resistance protein 1, MDR1). One of the most widely studied functional SNPs in ABCB1 gene is C3435T (rs1045642, ILe 1145ILe) in exon 26 [25] , which also has a higher frequency in Chinese population than that in other ethnic groups including Caucasian and African populations [26] [27] [28] . Other research groups have reported of a correlation between genetic polymorphisms of allergic response proteins, such as IgE receptor (FCERIA) and component 5a receptor 1 (C5AR1), and the therapeutic efficacy or side effects of mizolastine in vivo [29] [30] [31] . But whether genetic variants of UGT1A1, CYP3A5 and ABCB1 are associated with pharmacokinetic interindividual variation of mizolastine and whether these variant genotypes influence the metabolic phenotypes of mizolastine is still unknown.
In our previous studies, the significant interethnic differences in the SNP frequencies in the CYP3A5, CYP2C19, CYP2D6 and transporter ABCB1 genes have been observed between Chinese and Caucasian populations [32] [33] [34] . The correlations between genetic variants of CYP3A5 and ABCB1 and the interindividual differences have been detected in pharmacokinetics of immunosuppressant tacrolimus in Chinese liver transplant patients [35] . The objective of this study was to investigate the relationship between pharmacokinetic characters and genotypes, and then to evaluate whether UGT1A1, CYP3A5 and ABCB1 variant genotypes have effects on the pharmacokinetic phenotype of mizolastine in Chinese healthy volunteers.
Materials and Methods
Ethics. This study protocol was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committees at the Peking University Institutional Review Board (Permit Number: IRB00001052-05101) and China Food and Drug Administration (Permit Number:2005L03898). All the participants provided written consent, which has been the review procedure of the ethics committee.
Volunteers. Twenty-four healthy male Chinese Han ethnic volunteers were recruited for the mizolastine pharmacokinetics evaluation. The mean age, average weight and body mass index of the 24 volunteers were 25.60 (22) (23) (24) (25) (26) (27) (28) (29) , respectively. All of them were non-smokers and in good health as evaluated by physical examination and laboratory evaluation before entering the study. Participants were asked to abstain from smoking and caffeine during the study period.
DNA preparation and primer design. Genomic DNA was extracted from heparin-treated leucocytes in whole blood by QIAampâ DNA Blood Mini Kits (QIAGEN, Hilden, Germany). Single nucleotide polymorphisms (SNPs) in UGT1A1*6 (rs4148323, G211A in exon 1), CYP3A5*3 (rs776746, A6986G in intron 3) and ABCB1 (rs1045642, C3435T in exon 26) were determined in 24 Chinese volunteers [36] [37] [38] . SNP sequences were retrieved from dbSNP database (http://www. ncbi.nlm.nih.gov/projects/SNP/). Primers for SNP amplification and sequencing primers were designed using PSQ assay design software (QIAGEN). Primers, pyrosequencing analysis sequences and nucleotide dispensation orders are listed in Table S1 .
PCR for SNP amplification. [39] . PCRs of CYP3A5*3 and ABCB1 (C3435T) were performed with an initial denaturation for 5 min. at 94°C, followed by 35 cycles of denaturation for 30 sec. at 94°C, primer annealing for 30 sec. at 60°C and extension for 30 sec. at 72°C followed by a final extension for 5 min. at 72°C. The PCR condition of UGT1A1*6 consisted of one cycle of 94°C pre-denaturation for 5 min. and 50 cycles of amplification; each cycle was 30 sec. at 94°C, 30 sec. at 59°C, 30 sec. at 72°C and final extension for one cycle at 72°C for 10 min. All amplification reactions were performed with the Veriti TM 96-Well Thermal Cycler (Applied Biosystems, Foster City, CA, USA).
Pyrosequencing for genotyping. Pyrosequencing was performed on a PyroMark Q24 platform (QIAGEN), and the resulting pyrograms and associated sequences were generated and analysed automatically using PyroMark Q24 ID system (QIAGEN). The reagents used in pyrosequencing were all bought from QIAGEN GmbH and are shown as follows: PyroMark Gold Q24 Reagents, PyroMark binding buffer, PyroMark denaturation solution, PyroMark wash buffer and PyroMark annealing buffer.
Briefly, 50 lL amplified DNA products were mixed with 3 lL Streptavidin Sepharose TM High-Performance beads (GE Healthcare Bio. Sciences, Stockholm, Sweden) and 47 lL binding buffer, followed by shaking at 265 g for 10 min. Then, the immobilized biotinylated PCR products-streptavidin high-performance beads complex was captured using a vacuum prep tool. Single strand purification was achieved by washing the vacuum prep tool sequentially with 70% ethanol, denaturation solution and wash buffer, respectively, twice and each time for 30 sec. Through this step, the unbiotinylated strand was dissociated and discarded. The beads bound single biotinylated strands were released to a 24-well microtitre plate which was pre-added with 49 lL annealing buffer and 1 lL complementary sequencing primer. The plate was incubated at 80°C for 10 min., followed by slow cooling to room temperature. The processed mixture was loaded onto the PyroMark ID system equipped with PyroMark ID software for pyrosequencing. After that centrifuged at 1700 9 g for 10 min. at 4°C, and plasma samples were stored at À70°C until analysis.
Determination of mizolastine in plasma. Plasma concentrations of mizolastine were determined using a validated high-performance liquid chromatography (HPLC) method as described in previous publications [40] . Briefly, 500 lL of plasma was spiked with 50 lL of an internal standard (pioglitazone hydrochloride, 16 lg/mL) and then extracted with 4 mL of diethyl ether. The organic phase was evaporated at 50°C under a constant flow of nitrogen gas. The residue was reconstituted in 100 lL of mobile phase, and 20 lL was injected into the HPLC.
Pharmacokinetic analysis. The pharmacokinetic parameters of mizolastine were estimated by a non-compartment model using the program DAS 2.0 software (the Mathematical Pharmacology Committee, Chinese Pharmacological Society, Beijing, China). The plasma peak concentration (C max ) and the time to reach C max (T max ) were obtained directly from the experimental data. The areas under the plasma concentration-time curves from 0 to infinity (i.e. AUC 0-∞ ) and from 0 to 28 hr (AUC 0-28 ) were calculated by the trapezoidal summation. The terminal elimination rate constant (K e ) was derived from the slope of the linear regression curve by fitting the natural logarithms of the terminal concentrations versus time. The terminal elimination half-life (t 1/2 ) was calculated by 0.693/K e .
Statistical analysis. The frequencies of each polymorphism were compared between the different groups using Fisher's exact test. All concentrations of mizolastine were expressed as mean AE standard deviation (S.D.). The genetic frequencies of the different ethnic populations were compared by chi-square test or Fisher's exact test. The main pharmacokinetic parameters of mizolastine were compared by Dunnett's t-tests or one-way analysis of variance (ANOVA) among the different genotype groups by software SPSS 18.0 (IBM Analytics, Chicago, Illinois, USA). p < 0.05 was considered to be significant in the comparison.
Results
This study investigated genotypes of drug metabolism enzymes UGT1A1, CYP3A5 and transport ABCB1 by pyrosequencing method and evaluated whether these genetic variants are involved in the interindividual differences in the substrate pharmacokinetic phenotypes after an oral single dose of antihistamine mizolastine (10 mg) in the Chinese healthy volunteers. The chi-square test indicated that the frequencies of genotypes and alleles among the volunteers were compatible with the Hardy-Weinberg equilibrium (p > 0.05).
The plasma concentration-time courses of mizolastine. As shown in fig. 1 and table 1, after the single oral dose (10 mg/kg) of mizolastine in 24 Chinese healthy volunteers, the plasma peak concentrations (C max ) of mizolastine were 351.60 AE 68.51 ng/mL. The times to reach C max (T max ) were 1.83 AE 0.79 hr. The plasma elimination half-life period (t 1/2 ) of mizolastine was 5.13 AE 1.84 hr. After 28 hr of dosing, the plasma concentration of mizolastine was reduced at a very low level (33.79 AE 15.15 ng/mL). It has been reported that significant interindividual differences in mizolastine PK parameters were observed (e.g. the range of the t 1/2 was 6.1-25 hr) in Caucasians [41] . However, these results showed that the interindividual variability of mizolastine PK parameters was much smaller than that of previous reports, suggesting that there are different disposition profiles of mizolastine between Chinese and Caucasians ethnic populations. Detailed information regarding plasma concentration-time profiles of mizolastine after a single oral dose of 10 mg in Chinese healthy volunteers (n = 24) is listed in Table S2 .
Moreover, the area under the plasma concentration-time curves from 0 to 28 hr (AUC 0-28 ) and from 0 to infinity (i.e., AUC 0-∞ ) of mizolastine was 2441.50 AE 895.20 ng/mLÁhr and 2636.80 AE 955.10 ng/mLÁhr, respectively. Based on the AUC ratio between AUC 0-28 and AUC 0-∞ (AUC 0-28 /AUC 0-∞ ) representing the disposition capability of mizolastine in vivo, these results show that the AUC 0-28 /AUC 0-∞ ratio (%) of mizolastine was 92.51%. This result suggests that the marked difference was not observed between AUC 0-28 and AUC 0-∞ in mizolastine, and this dosage regimen design of 28 hr could be used for evaluating the terminal elimination phase of mizolastine.
Pharmacokinetics of mizolastine by UGT1A1*6 genotype. Sequencing results of UGT1A1*6 genotypes are shown in pyrograms by pyrosequencing method ( fig. 2A) . The distributions of UGT1A1*6 (211G>A) genotypes in 24 Chinese volunteers in the mizolastine pharmacokinetic study were as follows: UGT1A1*1/*1 (G/G) wild-type homozygotes were 70.8% (17 cases) and UGT1A1*1/*6 (G/A) variant heterozygotes (i.e. UGT1A1*6 allelic carrier) were 29.2% (seven cases), respectively. However, the UGT1A1*6/*6 (A/A) variant homozygotes were not observed in the 24 Chinese volunteers. Moreover, these results show that the frequency of UGT1A1*6 variant allele (14.6%, i.e. 7/(24 9 2) %) was similar to that reported in Chinese and Japanese while significantly different from Caucasians (0.07%, p < 0.05) and Africans in UGT1A1*6 allele variants (0.00%, p < 0.05) [16, 42, 43] . These results support the previous opinion that the allele UGT1A1*6 was more frequent in Asian ethnic groups, while it was missing or there were very few in Caucasians or Africans, suggesting that this genetic mutation might be involved in the interindividual differences of substrate drug such as mizolastine pharmacokinetics in Chinese volunteers. On the other hand, the plasma concentration-time curves ( fig. 2B-a) and pharmacokinetic parameters (table 2) of mizolastine according to UGT1A1*6 genotypes after a single oral administration of 10 mg mizolastine in the 24 Chinese healthy volunteers were as follows: the mean area under the curve from 0-to 28-hr point (AUC 0-28 ) of mizolastine in variant UGT1A1*1/*6 heterozygotes (UGT1A1*6 allele carriers, n = 17) and wild-type UGT1A1*1/*1 homozygotes (n = 7) were 2658.77 AE 1174.31 ng/mLÁhr and 2352.11 AE 778.29 ng/ mLÁhr, respectively (the ratio was 113.04%). The ratio of C max between variant UGT1A1*6 carriers and wild-type UGT1A1*1/*1 homozygotes was 101.03% (354.15 AE 57.96 versus 350.55 AE 74.05 ng/mL).
Moreover, in spite of the parameter T max of mutant heterozygous UGT1A1*1/*6 (UGT1A1*6 carriers) was prolonged to 162.35% of wild-type UGT1A1*1/*1 homozygotes (2.36 AE 1.03 versus 1.62 AE 0.57 hr), the significant differences in the pharmacokinetic parameters of the mizolastine including C max, T max, AUC 0-28 and t 1/2 were not observed between variant UGT1A1*6 allelic carriers and wild-type UGT1A1*1/*1 homozygous genotypes in Chinese volunteers (all of p values > 0.05). Furthermore, in order to be more informative and clear about the specific pharmacokinetic profile in different individuals, the AUC 0-28 among different UGT1A1*6 genotype groups was compared and is shown in fig. 2B-b (box-and-whisker plots) . Detailed information regarding mean pharmacokinetic parameters including different groups and individuals by genotyping are listed in Tables S3 Fig. 2. Pyrograms (A) showing the raw data for UGT1A1*6 genotypes from A (a) wild-type homozygotes (GG) and A (b) variant heterozygotes (GA) by pyrosequencing assay. The first peak in the pyrograms is the 'substrate peak' that always occurs when adding the reagents at the beginning of the pyrosequencing run. The shaded background indicates position where diagnostic peaks appear. Note that UGT1A1*6 assays are reverse assays, with C for G and T for A. The y-axis is number of incorporated nucleotides determined by relative light units and x-axis is time in min. by sequencing dispensation order. Plasma concentration-time curves B (a) and area under the curve from 0-to 28-hr point (AUC 0-28 ) B (b) of mizolastine according to UGT1A1*6 genotypes after a single oral administration of 10 mg mizolastine in 24 Chinese healthy volunteers. Each value represents the mean AE S.D. Solid circles, UGT1A1*1/*1 (n = 17). Solid quadrates, UGT1A1*1/*6 (n = 7). and S4, respectively. Moreover, the original data regarding plasma concentration-time courses and pharmacokinetic parameters in the 24 volunteers are listed in Tables S5 and  S6 , respectively.
Pharmacokinetics of mizolastine by CYP3A5 genotype.
Sequencing results of CYP3A5*3 genotypes are shown in pyrograms by pyrosequencing method (fig. 3A) . The distributions of CYP3A5*3 (6986 A>G) genotypes in the 24 Chinese volunteers in the mizolastine pharmacokinetic study were as follows: CYP3A5*3/*3 (G/G) variant homozygotes were 41.7% (10 cases, CYP3A5*3 allele carriers), CYP3A5*1/*3 (G/A) variant heterozygotes were 37.5% (nine cases, CYP3A5*3 allele carriers) and CYP3A5*1/*1 (A/A) wild-type homozygotes were 20.8% (five cases), respectively. Moreover, these results show that the frequency of CYP3A5*3 variant allele (60.4%, 29/48) was similar to what we have previously observed in Chinese, while it was significantly different from that in Caucasians (91.70%, p < 0.05) and Africans (20.83%, p < 0.05) [32, 44, 45] . On the other hand, the plasma concentration-time curves ( fig. 3B-a) and pharmacokinetic parameters (table 3) of mizolastine according to CYP3A5 genotypes after a single oral dose of 10 mg mizolastine in the 24 Chinese healthy volunteers were as follows: the mean AUC from 0-to 28-hr point (AUC 0-28 ) of mizolastine in variant CYP3A5*3/*3 homozygotes (CYP3A5*3 allele carriers, n = 10), variant CYP3A5*1/*3 heterozygotes (CYP3A5*3 allele carriers, n = 9) and wild-type CYP3A5*1/*1 homozygotes (n = 5) was 2076.98 AE 600.74 ng/mLÁhr, 2550.24 AE 940.08 ng/mLÁhr and 2975.04 AE 1146.24 ng/mLÁhr, respectively ( fig. 3B-b) . Moreover, the C max of variant CYP3A5*3/*3 homozygotes, variant CYP3A5*1/*3 heterozygotes and wild-type CYP3A5*1/*1 homozygotes was 331.63 AE 40.33, 349.48 AE 76.36 and 395.34 AE 90.93 ng/mL, respectively. The T max was 1.58 AE 0.65, 2.11 AE 0.89 and 1.85 AE 0.82 hr, respectively. The t 1/2 was 4.79 AE 1.58, 4.72 AE 1.94 and 6.57 AE 1.77 hr, respectively (all of p values > 0.05).
Pharmacokinetics of mizolastine by ABCB1 (C3435T) genotype. Sequencing results of ABCB1 genotypes are shown in pyrograms by pyrosequencing method (fig. 4A ). The distributions of ABCB1 (C3435T) genotypes in the 24 Chinese volunteers in the mizolastine pharmacokinetic study were as follows: ABCB1 (T/T) variant homozygotes were 20.8% (five cases, ABCB1 T allele carriers), ABCB1 (C/T) variant heterozygotes were 50.0% (12 cases, ABCB1 T allele carriers) and ABCB1 (C/C) wild-type homozygotes were 29.2% (seven cases), respectively. These results show that the frequency of ABCB1 T variant allele [45.8%, i.e. (5 9 2 + 12)/(24 9 2) = 22/48%] was similar to what we previously observed in Chinese, while it was significantly different from Caucasians (46.40%, p < 0.05) and Africans (12.10%, p < 0.05) [32, [46] [47] [48] .
On the other hand, the plasma concentration-time curves ( fig. 4B-a) and pharmacokinetic parameters (table 4) of mizolastine according to ABCB1 (C3435T) genotypes after a single oral administration of 10 mg mizolastine in 24 Chinese healthy volunteers were as follows: the mean AUC from 0-to 28-hr point (AUC 0-28 ) of mizolastine in variant ABCB1 TT homozygotes (ABCB1 T allele carriers, n = 5), variant ABCB1 CT heterozygotes (ABCB1 T allele carriers, n = 12) and wildtype ABCB1 CC homozygotes (n = 7) was 3090.00 AE 1032.97, 2289.03 AE 735.69 and 2239.84 AE 961.24 ng/mLÁhr, respectively ( fig. 4B-b) . Moreover, the C max of variant ABCB1 TT homozygotes, variant ABCB1 CT heterozygotes and wild-type ABCB1 CC homozygotes was 380.52 AE 57.22 ng/mL, 347.61 AE 43.58 ng/mL and 337.77 AE 106.66 ng/mL, respectively. The T max was 2.00 AE 0.61 hr, 2.02 AE 0.92 hr and 1.39 AE 0.50 hr, respectively. The t 1/2 was 6.78 AE 1.56 hr, 4.47 AE 1.65 hr and 5.10 AE 1.80 hr, respectively (all of p values > 0.05).
Discussion
Pyrosequencing has been reported to be a technique used to rapidly and accurately analyse short DNA sequences with high throughput for the identification and genotyping of SNPs [49, 50] . This method is based on the detection of released pyrophosphate (PPi) during DNA synthesis, which involves the hybridization of a primer to a single-stranded PCR template, and a cascade of the enzymatic reactions started by a nucleic acid polymerase to add nucleotides [51] . In the cascade, the released PPi is converted to ATP by ATP sulfurylase, which provides the energy to luciferase to oxidize luciferin and generate light [52] . Subsequently, visible light peak is proportional to the number of incorporated nucleotides in a monitor pyrogram. Because the added nucleotide is known, the sequence of the template can be determined [53] . Compared with other genotyping methods, pyrosequencing is in no need of electrophoresis and fluorescent labelling of target DNA fragments [54] . This research investigated that the genetic variants of UGT1A1, CYP3A5 and ABCB1 (C3435T) analysed by the pyrosequencing method in the Chinese volunteers indicate that the polymorphism profiles were similar to the previous reports that the marked ethnic-difference between Chinese and Caucasians evaluated by the classical PCR-RFLP method, and suggest that the pyrosequencing method is appropriate to analyse genotype of metabolic enzymes in clinical samples. Conversely, UGT1A1*6 has been reported to be the most common allele correlated with reduced glucuronidation activity and drug toxicity in vivo [20, 55, 56] . However, these results show that no significant differences in mizolastine pharmacokinetic parameters were observed between variant UGT1A1*6 allelic carriers and wild-type UGT1A1*1/*1 homozygote genotypes in the 24 Chinese volunteers, suggesting that the genetic variants of UGT 1A1 alone do not explain the interindividual differences in UGT1A1-mediated metabolism.
Similarly, these results show that the ratios of the pharmacokinetic parameters of mizolastine were not observed significantly different between variant ABCB1 T allele carriers (the sum of the variant ABCB1 CT heterozygotes and the variant ABCB1 TT homozygotes) and wild-type ABCB1 CC homozygotes (all of p values > 0.05), suggesting that the genetic variant of ABCB1 (C3435T) is also not likely to associate with the interindividual differences in ABCB1-mediated transport and disposition of antihistamine mizolastine in Chinese volunteers.
Furthermore, although the tendency of gene-dose-dependent effect in AUC 0-28 , C max , T max and t 1/2 has been observed between variant CYP3A5*3 allele carriers (the sum of the variant CYP3A5*1/*3 heterozygotes and the variant CYP3A5*3/*3 homozygotes) and wild-type CYP3A5*1/*1 homozygotes; however, the ratios of the pharmacokinetic parameters were not significantly different between variant CYP3A5*3 allele carriers and wild-type CYP3A5*1/*1 homozygotes (all of p values > 0.05). These results suggest that the genetic variant of CYP3A5 might also not influence the interindividual differences in CYP3A5-mediated metabolism of the antihistamine mizolastine in the Chinese volunteers. Moreover, inclusion of female volunteers and evaluation of gender differences might add value to the antihistamine mizolastine individualized medication study.
Conclusion
This research is the first report that the genetic variants of UGT1A1, CYP3A5 and ABCB1 (C3435T) analysed by the pyrosequencing method in the Chinese volunteers, indicating that the polymorphism profiles were similar to the previous reports that the marked ethnic difference between Chinese and Caucasians evaluated by the classical genotyping methods, and suggesting that the pyrosequencing is appropriate for genotyping in clinical samples. On the other hand, these results show that the significant differences in pharmacokinetic parameters of mizolastine were not observed between the variant UGT1A1*6, CYP3A5*3 and ABCB1 (C3435T) allele carriers and the wild-type homozygotes after oral dose of mizolastine, suggesting that UGT1A1, CYP3A5 and ABCB1 genetic variants might not contribute to the interindividual variations in these metabolic enzymes and transportermediated mizolastine pharmacokinetic phenotype and disposition in Chinese individuals. 
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